
    
      The duration of the study will include a period for screening of up to a maximum of 28 days,
      a pretreatment evaluation period of up to 5 days, the on-treatment period, followed by a
      minimum of 30-day follow-up after the last study drug administration.

      The patient may continue study treatment until disease progression, unacceptable toxicity, or
      consent withdrawal.

      The study will have 2 parts:

        -  Part one - Dose Escalation

        -  Part Two - Expansion. At the defined maximum tolerated doses (MTD(s), additional
           patients will be enrolled to collect safety, Pharmacokinetic, and Pharmacodynamic data
    
  